BRIEF-Scynexis Initiates Phase 1 Study Of Scy-770, A Novel Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease (Adpkd)

SCYNEXIS, Inc.

SCYNEXIS, Inc.

SCYX

0.00

June 30 (Reuters) - SCYNEXIS Inc SCYX.O:

  • SCYNEXIS INITIATES PHASE 1 STUDY OF SCY-770, A NOVEL AMPK ACTIVATOR FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)

  • SCYNEXIS - PHASE 2 STUDY IN ADPKD EXPECTED TO BEGIN IN Q4 2026

  • SCYNEXIS - TOPLINE PHASE 1 DATA EXPECTED IN Q3 2026

Source text: ID:nGNX7N5Sv5

Further company coverage: SCYX.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.